INDOLENT NON-HODGKIN LYMPHOMA
Clinical trials for INDOLENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new INDOLENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for INDOLENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 17, 2026 07:07 UTC
-
Engineered immune cells shrink tumors in Hard-to-Treat lymphoma
Disease control CompletedThis study tested a one-time treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 159 adults with follicular or marginal zone lymphoma that had not responded to at least two prior treatments. The therapy works by reprogramming a patient's own immune cells to attack …
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…
Matched conditions: INDOLENT NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:02 UTC